8-K - Aethlon Medical, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Aethlon Medical, Inc. reported financial results for its fiscal third quarter ended December 31, 2025, including a net loss of $2.02 million and a cash balance of $7.0 million, while providing updates on clinical trial progress and operational cost efficiencies.

Key Takeaways

1Reported a net loss of $2.02 million for the quarter ended December 31, 2025, compared to a net loss of $1.75 million in the prior year period.

2Had a cash balance of approximately $7.0 million as of December 31, 2025.

3Operating expenses for the quarter increased 13.6% to $2.06 million, primarily due to higher payroll costs.

4Operating expenses for the nine months ended December 31, 2025 decreased 26.9% to $5.36 million compared to the same period in 2024.

5Cohort 2 of the Australian oncology trial is actively progressing, building on Cohort 1 results.

6Maintained Nasdaq listing compliance with all prior compliance matters resolved.

Current Report Details

Event Type

Financial Results

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

. Item 7.01 Regulation FD Disclosure. On February 12, 2026, Aethlon Medical, Inc. (the “Company”) issued a press release regarding its financial results for the

Financial Results

7.01

of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exch

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated February 12, 2026 104 Cover Page Interactive Data File (embedd

Exhibits Only

Source Document

Results of Operations

Fiscal Third Quarter 2026

Metric	Value	Prior Period
Operating Loss	$2.1M	$1.8M
Net Loss	$2.0M	$1.8M
Basic and Diluted Loss Per Share	$2.45	$10.05

Exhibits (2)

8-K

CURRENT REPORT

99.1

PRESS RELEASE